

## Company Overview

Cytovia Therapeutics, Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia Therapeutics focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma.


## Company Highlights

- Multiple Hematological & Solid Tumor Therapeutic Candidates, expected to enter clinical trials starting in 2021
- Two state-of-the-art technology platforms to unlock the power of NK Cells
- World Class Scientific Partnerships
- Experienced Entrepreneurial Management Team

*"Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."*

*- Daniel Teper, Cytovia Therapeutics CEO*

### Building a leader in NK Therapeutics



Series A 50m – Series B Crossover Round 2021

Multiple Value Inflection points

## World-Class Partnerships

**NYSCF**

The New York  
Stem Cell Foundation

*Collaboration with acknowledged pioneer and leader in stem-cell technology to advance production of CAR-NK from induced-pluripotent stem cells.*

**UCSF**

*Research partnership focused on utilizing next-gen gene-editing technology to develop precision CAR NK cell therapeutics for both solid and hematological cancers*



*Strategic collaboration to develop bispecific and trispecific NKp46 engagers.*

**MacroMolTEK**  
Molecular simulations simplified

*Artificial intelligence company out of the Y Combinator incubator, dedicated to the advancement of antibody drug development, allowing for fast-tracking of antibody design and development of optimal therapeutic candidates in weeks rather than months.*

## Leadership

**Daniel Teper, PharmD, MBA**  
Chairman & CEO

**Wei Lu, PhD**  
Chief Scientific Officer

**Dan Chiche, MD**  
SVP, Clinical Development

**Sophie Badré, MS**  
VP, Corporate Affairs

**Armin Rath, PhD**  
VP, Business Development & Alliance Management

**Anna Baran-Djokovic, LLM**  
VP, Investor Relations

## Board of Directors

**Leila Alland, MD**  
Board Director

**Laurent Audoly, PhD**  
Board Director

**Michael Friedman, MD**  
Board Director

**Massimo Radaelli, PhD, MBA**  
Co-Founder & Board Director

**Tom Robinson, MBA**  
Board Director

**Gilles Seydoux, PharmD**  
Co-Founder & Board Director

**Daniel Teper, PharmD, MBA**  
Co-Founder & Chairman

**Jane Wasman, JD**  
Board Director

## Broad Biopharma Experience



Bristol-Myers Squibb



Cardinal Health



City of Hope



## About NK Cells

NK cells are the first line of immune defense against cancers and infectious diseases. They allow for therapies that offer major safety and usability advantages over T-Cell Therapies. While highly cytotoxic to the cancer cells, they do not cause Cytokine Release Syndrome or neurotoxicity - main risks of CAR-T and T-cell engagers. NK Cells are naturally allogeneic and available off-the-shelf and on-demand with fast delivery time, a key to better patient outcomes.

## State-of-the-Art Technology: Advantages of iPSC CAR-NKs

Induced Pluripotent Stem Cells (iPSCs) are undifferentiated stem cells which can be differentiated into NK and CAR-NK cells. Each CAR-NK product can be produced on demand at scales of millions of cells from Master Cell Banks, ensuring product homogeneity, easy gene-editing at the level of the stem cell, and subsequent scalability and cost-effectiveness.

## Advantages of NKp46 engagers

NKp46 engagers are bi-specific or trispecific antibodies that target a specific tumor antigen while leveraging the power of the innate immune system (NK Cells). NKp46 is a natural cytotoxicity receptor for more NK-cells in hematological and solid tumors. NKp46 increases not only cytotoxic activity but also cytokine release. NKp46 targeting & activation results in significantly better tumor control than available clinical antibodies with no off-target toxicities. A 2019 Cell paper highlights the power of NKp46 as an NK engager in bi- and tri-specific antibodies.

## Therapeutic Candidates

Cytovia Therapeutics is addressing crucial unmet medical needs with validated targets and state-of-the-art technologies. Priority indications are hepatocellular carcinoma (HCC), multiple myeloma, and glioblastoma.

- Hepatocellular carcinoma is the 3rd most common cause of cancer deaths worldwide, with around 800,000 new cases and 700,000 deaths annually. The GPC3 receptor targeted by our CAR-NK is expressed in 75% of HCC tumor cells.
- Multiple Myeloma affects 190,000 new patients annually (32,270 in the US). In refractory patients, BCMA CAR-T showed close to 100% response rate but over 70% Cytokine Release Syndrome (CRS) – our NK technology is available off-the-shelf, allowing for timely treatment, and is expected to lead to high response rates without CRS.
- Glioblastoma ranks amongst the deadliest cancers, with 290,000 new patients annually (27,000 in the US) and a median survival rate of only at 14.6 months despite current treatment options. Dual targeting of EGFR vIII/wt has demonstrated benefit in most patients, with intracranial CAR NK cell therapy limiting toxicity and providing a timely off-the-shelf option.

## A Diversified Pipeline with Multimodal Approaches to Provide Optionality Key Value Inflection Points Expected in 2021-2023

	Candidate	Target	Indications	IND	Phase 1	Phase 2 / Pivotal
CAR-NK Cell therapies	CYT-101	EGFR	GBM / Solid Tumors		Q4 2021	2023
	CYT-102	GPC3	HCC / Liver		2022	2023
	CYT-104	CD38	Multiple Myeloma		2022	2023
NK Engager Multi-specific Antibodies	CYT-106	NKp46E-CD38	Multiple Myeloma		Q4 2021	2023
	CYT-107	NKp46E-GPC3	Solid Tumors		Q4 2021	2023

Contact  
Information:

80 SW 8th Street - Suite 2000  
Miami, FL, 33130  
[www.cytoviatx.com](http://www.cytoviatx.com)

[sophie.badre@cytoviatx.com](mailto:sophie.badre@cytoviatx.com)  
US: +1 (929) 317 1565